Home/ Stocks/ GRCE

Grace Therapeutics, Inc. Common Stock

GRCE XNAS

$2.13 +0.05 (+2.17%) ▲ 15-min delayed

Open

$2.13

High

$2.16

Low

$2.10

Volume

120.4K

Market Cap

$34.50M

About Grace Therapeutics, Inc. Common Stock

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 5 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2026	N/A	$-7,793,000	$-0.47
FY 2026	N/A	$-7,793,000	$-0.47
Q3 2026	N/A	$-2,315,000	$-0.14
Q2 2026	N/A	$-938,000	$-0.06

Related Market News

No specific coverage for GRCE yet. Check out our latest market news or earnings calendar.

Get GRCE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Grace Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.